SF3B1 and acute myeloid leukemia: There was a statistically significant difference in shorter overall survival and higher risk of AML progression in patients with co-occurrence of SF3B1 and DNMT3A mutation than those with SF3B1mut but DNMT3A wild type (Martin et al., 2017).